Key Capital announces positive liver cancer immunotherapy results: 7 insights

Key Capital announced positive results for its liver cancer immunotherapy product hepcortespenlisimut-L.

Here's what you should know.

1. Hepcortespenlisimut-L is a once daily tablet of an oral immunotherapeutic vaccine.

2. Key Capital proved it was safe and highly effective in treating 75 advanced liver cancer patients through a phase II study.

3. More than 90 percent of patients were alive after a 12 month follow-up. A competitor product touts a 10 percent survival rate.

4. After two months, 50 of the 75 patients had their hepatic tumor marker decline, indicating a 66.7 percent response rate.

5. Twelve patients had normal alpha-fetoprotein levels experienced tumor clearance.

6. Researchers observed no adverse events at the time.

7. Key Capital is in the midst of a phase III study at Mongolian National Cancer Center in China.

More articles on gastroenterology:
Inflammatory bowel disease value-based model improves outcomes, lowers costs: 3 study insights
GI leader to know: Dr. Matthew Grossman of Gastroenterology Associates of New Jersey
Water exchange increases adenoma detection rate over alternatives: 5 study insights

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Top 40 Articles from the Past 6 Months